Abiomed (NASDAQ:ABMD), a leading provider of novel percutaneous cardiac assist devices that are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart, has seen its revenues increased by more than 100% in the last four years.
ABMD Revenue Per Share (TTM) data by YCharts
Abiomed's Impella range of heart pumps has enormous growth potential in the treatment of cardiovascular diseases. Although the stock price of Abiomed has more than doubled itself in the last one year, I believe there is still some room for price appreciation over the medium term. In this article I will analyze the future prospects of Impella, Abiomed's lead product and its potential impact on...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|